Consensus EyePoint, Inc.

Stocks

EYPT

US30233G2093

Pharmaceuticals

Real-time Estimate Cboe BZX 07:48:05 13/11/26 am AEDT			5-day change	1st Jan Change
0.3280 ^USD	-8.02%		-8.40%	-98.22%

01:35am	EyePoint, Inc., Q3 2026 Earnings Call, Nov 12, 2026
01:21am	EyePoint, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI

Evolution of the Average Target: EyePoint, Inc.

Evolution of the Target Price: EyePoint, Inc.

Changes in Analyst Recommendations: EyePoint, Inc.

d966a.pFDM1_XgagHL5O3gXdLuMtaOXaD-udL_DRcEAM3GLvE.kQmrv72DX1OJkKPYLOagdp_tNuqKiqKTRnQ9RZu1H67QYoeggakvWLGhrA~6730064feb25b57f73a5fd11cef86a7c

Analysts' recommendations: EyePoint, Inc.

21/10	Ocular Therapeutix Has 75% Success Probability for Axpaxli in Wet Age-Related Macular Degeneration, UBS Says	MT
21/10	EyePoint's DME Study Readout a Catalyst After wAMD Trial Misses Endpoint, RBC Says	MT
21/10	Laidlaw Downgrades EyePoint Pharmaceuticals to Hold From Buy	MT
20/10	JPMorgan Downgrades EyePoint Pharmaceuticals to Underweight From Neutral	MT
20/10	RBC Capital Adjusts Price Target on EyePoint Pharmaceuticals to $1 From $5, Keeps Sector Perform, Speculative Risk	MT
20/10	Mizuho Downgrades EyePoint Pharmaceuticals to Neutral From Outperform, Adjusts PT to $0.50 From $39	MT
20/10	Guggenheim Downgrades EyePoint to Neutral From Buy	MT
20/10	Jefferies Downgrades EyePoint Pharmaceuticals to Hold From Buy, $1 Price Target	MT
02/09	TD Cowen Downgrades EyePoint Pharmaceuticals to Hold From Buy, Adjusts PT to $4 From $20	MT
19/08	EyePoint Faces Regulatory Uncertainty After Lugano Trial Miss, RBC Capital Markets Says	MT
18/08	Chardan Downgrades EyePoint Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $5 From $65	MT
18/08	RBC Downgrades EyePoint to Sector Perform From Outperform, Cuts Price Target to $5 From $37, Keeps Speculative Risk	MT
18/08	HC Wainwright Downgrades EyePoint Pharmaceuticals to Neutral From Buy	MT
18/08	JPMorgan Downgrades EyePoint Pharmaceuticals to Neutral From Overweight	MT
05/08	Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says	MT
29/07	Mizuho Raises Price Target on EyePoint Pharmaceuticals to $39 From $36, Keeps Outperform Rating	MT
16/07	Stifel Initiates EyePoint Pharmaceuticals at Buy With $40 Price Target	MT
01/07	Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating	MT
08/05	RBC Capital Adjusts EyePoint Pharmaceuticals PT to $37 From $39, Maintains Outperform Speculative-Risk Rating	MT
05/03	Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating	MT
07/11	RBC Raises Price Target on EyePoint Pharmaceuticals to $39 From $28, Keeps Outperform, Speculative Risk	MT
15/10/25	Cooking oil, hot markets
15/08/25	Mizuho Adjusts Price Target on EyePoint Pharmaceuticals to $28 From $26, Maintains Outperform Rating	MT
17/06/25	RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target	MT
16/05/25	Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EYEPOINT, INC.					+2,266.1%
	ELI LILLY AND COMPANY					+1.12%
	JOHNSON & JOHNSON					-0.36%
	ABBVIE INC.					+5.31%
	ROCHE HOLDING AG					-1.37%
	MERCK & CO., INC.					+9.75%
	NOVARTIS AG					-3.31%
	ASTRAZENECA PLC					+16.26%
	AMGEN INC.					-7.76%
	GILEAD SCIENCES, INC.					+2.97%
	Average					+228.87%
	Weighted average by Cap.					+2.19%